Moberg Pharma’s fungal nail product approved in China

Moberg Pharma AB (OMX: MOB) today announced that its partner, Menarini Asia-Pacific, has received approval for Moberg’s fungal nail product in China. Launch preparations in several markets are progressing ahead of plan.

Moberg Pharma’s distribution agreement with the Menarini Group – a top 40 global pharmaceutical company – includes Italy, China and eight countries in Southeast Asia. Menarini has in addition initiated launch activities in Malaysia, Singapore and Hong Kong and preparations are ongoing in the other markets in the region.

“We are excited about the progress that Menarini Asia-Pacific has made in registration and launch preparation activities. Kerasal Nail® has significant potential in the region. Assuming successful launches, the region will be an important contributor to revenues and earnings from 2015 and onwards,” said Peter Wolpert, CEO of Moberg Pharma AB.

About this information

Moberg Pharma discloses this information pursuant to the Swedish Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 08:30 am (CET) on January 27, 2015.